Article Text

Download PDFPDF
What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? ‘Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors ML and HT drafted and finalised the paper together.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests ML and HLT have no competing interests directly related to this manuscript; ML received research funding from Gilead US company and Viiv company. ML gave consultancies to MSD and Viiv. HLT’s wife is a full-time employee of AbbVie and holds stocks in AbbVie, Abbott and Gilead. HLT served as a DSMB chair to a Novartis.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles